Successful desensitisation in a patient with CRIM-positive infantile-onset pompe disease

JIMD Reports

Volumn 12, Issue , 2014, Pages 99-102

  Baruteau, J ^a   Broomfield, A ^a   Crook, V ^a   Finnegan, N ^a   Harvey, K ^a   Burke, D ^a   Burch, M ^a   Shepherd, G ^b   Vellodi, A ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Desensitisation protocol; Enzyme replacement therapy; Fabry disease; Glycogen storage disease; Pompe disease

Indexed keywords

EID: 84941275612     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2013_250     Document Type: Chapter

References (18)

1. Akdis M, Akdis CA (2007) Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 119:780–791
2. Bali DS, Goldstein JL, Banugaria S et al (2012) Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet 160:40–49
3. Banugaria SG, Prater SN, Ng YK et al (2011) The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med 13:729–736
4. Banugaria SG, Prater SN, Mcgann et al (2013) Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med 15:123–131
5. Bodensteiner D, Scott CR, Sims KB et al (2008) Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme. Genet Med 10:353–358
6. Burton BK, Whiteman DA (2011) Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). Mol Genet Metab 103:113–120
7. Castells MC, Tennant NM, Sloane DE et al (2008) Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122:574–580
8. Cernadas JR, Brockow K, Romano A et al (2010) General considerations on rapid desensitization for drug hypersensitivity – a consensus statement. Allergy 65:1357–1366
9. El-Gharbawy AH, Mackey J, Dearmey S (2011) An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions. Mol Genet Metab 104:118–122
10. Kim KH, Decker C, Burton BK (2008) Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme]). Pediatrics 121: e714–e717
11. Kishnani PS, Corzo D, Nicolino M et al (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99–109
12. Kishnani PS, Goldenberg PC, Dearmey SL et al (2010) Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99:26–33
13. Lipinski SE, Lipinski MJ, Burnette A et al (2009) Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa. Mol Genet Metab 98:319–321
14. Messinger YH, Mendelsohn NJ, Rhead W et al (2012) Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med 14:135–142
15. Nicolino M, Byrne B, Wraith JE et al (2009) Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 11:210–219
16. Peroni DG, Pescollderungg L, Piacentini GL et al (2009) Effective desensitization to imiglucerase in a patient with type I Gaucher disease. J Pediatr 155:940–941
17. Van Den Hout HM, Hop W, Van Diggelen OP et al (2003) The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112:332–340
18. Wachholz PA, Durham SR (2003) Induction of ‘blocking’ IgG antibodies during immunotherapy. Clin Exp Allergy 33:1171–1174